We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




"Fetal Cell Transplant” Could be Link Between Reduced Risk of Breast Cancer and Motherhood

By Biotechdaily staff writers
Posted on 17 Oct 2007
Some benefits of motherhood are elusive, but one has been validated through biostatistical studies: women who bear children have a reduced risk of developing breast cancer. More...


In Seattle (WA, USA), researchers at the University of Washington and Fred Hutchinson Cancer Research Center believe they have identified a source of this protective effect: fetal cells "transplanted” to the mother before birth. Their findings were described in the October 1, 2007, issue of the journal Cancer Research.

The ability of cells from a growing fetus to take up long-term residence within its mother is a process called fetal microchimerism. According to the investigators, while fetal microchimerism has been implicated as a mechanism of autoimmune disease, it may also benefit mothers by putting the immune system on watch for malignant cells to destroy.

To test the hypothesis, the researchers recruited 82 women, 35 of whom had been diagnosed with breast cancer. About two-thirds of the women evaluated have had children, and more than 50% of the participants had given birth to at least one son. The researchers took blood samples from each participant and searched them for male DNA, as they believed it is a comparatively definitive matter to detect the male Y chromosome amid the mother's native--and distinctly female--cells within a blood sample.

Among the women with breast cancer, only five had male DNA in their bloodstream. Three of the five previously gave birth to sons, one had had an abortion, and the other had never been knowingly pregnant. In total, approximately 14% of all women in the breast cancer group had male DNA in their bloodstream compared to 43% of women in the non-breast cancer group.

"Our research found that these persisting fetal cells may be giving a woman an edge against developing breast cancer,” said lead author Vijayakrishna K. Gadi, M.D., Ph.D., assistant professor at the University of Washington and research associate at the Fred Hutchinson Cancer Research Center. "This experiment of nature is all the more fascinating because for years doctors treated a number of different cancers by transplanting cells from one person to another.”

According to Dr. Gadi, these results could provide a starting point for future research on the role of fetal microchimerism in the prevention of cancer. Moreover, there are other reasons for male DNA to be in a woman's peripheral blood, such as miscarriage and abortion, or perhaps even blood transfusion or a male twin that was reabsorbed into the womb at an early stage of the pregnancy.


Related Links:
University of Washington
Fred Hutchinson Cancer Research Center

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.